Tiziana appoints Intercept head to its board
September 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing roberto pelliccaiari, tiziana
UK biotech firm Tiziana Life Sciences has confirmed that Professor Roberto Pellicciari is joining its scientific advisory board and will …
UK pharma pays out £150m in drug rebates
September 12, 2014Medical Communications, Sales and Marketing ABPI, PPRS, Roche, emms, rebate
The UK pharma industry has paid £150 million back to the government as part of its rebate to “underwrite the …
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Google’s Calico takes first steps into research
September 12, 2014Medical Communications, Sales and Marketing AbbVie, P7C3, Parkinson's, Parkinson’s, calico, depression, google, motor neurone disease
Google is finally shifting into gear within the health arena as it signs its first research deal to develop a …
Cerenis announces board chairman
September 12, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerenis
France and US-based biopharma firm Cerenis Therapeutics has confirmed the appointment of Dr Richard Pasternak as its chairman of the …
Lilly and Boehringer diabetes biosimilar sees EU approval
September 11, 2014Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly
Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …
FDA approves new indication for Xtandi
September 11, 2014Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate
The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …
Fourth diet pill makes it to US market
September 11, 2014Manufacturing and Production, Sales and Marketing Contrave, FDA, Orexigen Therapeutics, diet, obesity
Orexigen Therapeutics has gained FDA approval for its new obesity treatment Contrave to help overweight patients reduce their food intake. …
90TEN Healthcare appoints comms director
September 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 90TEN, Lottie Tupholme, Peter Impey, Steve Ramsey
London comms agency 90TEN Healthcare has hired Peter Impey as its director of international communications, and added two heads to …
NICE seeks more trial data from pharma
September 10, 2014Medical Communications, Research and Development, Sales and Marketing David Haslam, NICE, Tamiflu, alltrials, transparency
NICE is calling on pharma to release more data so it can better assess the costs of new medicines.The watchdog …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
Apple launches health-centred smartwatch
September 10, 2014Medical Communications, Research and Development, Sales and Marketing Android, Apple, Jobs, Samsung, apple watch, google, health kit
Apple has finally unveiled its long-rumoured ‘smartwatch’ to the world along with new iPhones and a payment system. At the …
Trial misconduct halts Evotec/Hyperion drug
September 10, 2014Research and Development, Sales and Marketing DiaPep277, Evotec, amdromeda, diabetes, hyperion
Development of Evotec and Hyperion Therapeutic’s diabetes drug DiaPep277 has been terminated following ‘serious misconduct’ in one of its trials. …
Liberation appoints account co-ordinator
September 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Edward Mullin, Liberation, communications
UK-based healthcare comms agency Liberation has hired a new starter to its team with the appointment of Edward Mullin as …
Federal Trade Commission sues AbbVie and Teva
September 9, 2014Manufacturing and Production, Sales and Marketing AbbVie, FTC, Teva, androgel, federal trade commission
Authorities in the US claim that AbbVie and Teva filed ‘sham’ lawsuits in a complicated pay-to-delay case for generic forms …
‘Pocket doctor’ on the horizon for Parkinson’s
September 9, 2014Medical Communications, Sales and Marketing Nonlinearity and Complexity Research Group, Parkinson's, aston, dr little, pocket doctor
Smartphones will soon be able to perform the functions of a ‘pocket doctor’ and map Parkinson’s disease and other degenerative …
Celgene rebuffed by NICE over cancer drug
September 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel
In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …
New chief executive and chairman for Evaluate
September 9, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing alex karle, evaluate
Life science market intelligence firm Evaluate has appointed Alex Karle to the role of chief executive, replacing the firm’s founder Dr …
New chief executive for ReNeuron
September 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Olav Hellebø, ReNeuron, clavis
UK-based stem cell therapy firm ReNeuron has appointed Olav Hellebø to be its new chief executive. Since starting his pharma …
NHS cancer services not holding up, says report
September 8, 2014Research and Development, Sales and Marketing CRUK, Cancer, NHS, UK, government, oncology
NHS cancer services are in urgent need of investment and review, according to a new report commissioned by Cancer Research …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
